Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Artru

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Journal of the National Cancer Institute|February 4, 2016
Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO StudyDavid Tougeron, Guillaume Mouillet, Isabelle Trouilloud, et al.
International Journal of Cancer|January 24, 2020
Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter studyDavid Tougeron, Benjamin Sueur, Aziz Zaanan, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2024
Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world studyJeannie M'Baloula, David Tougeron, Alice Boilève, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 7, 2023
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO studyElisabeth S Bergen, Lorenzo Pilla, Edouard Auclin, et al.
Cancers|July 24, 2021
Management of Patients with Pancreatic Ductal Adenocarcinoma in the Real-Life Setting: Lessons from the French National Hospital DatabaseChristelle de la Fouchardière, Mustapha Adham, Anne-Marie Marion-Audibert, et al.
Oncotarget|December 20, 2017
Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO studyJuliette Palle, David Tougeron, Astrid Pozet, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 5, 2025
Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)Thierry Lecomte, Bruno Giraudeau, Jean-Marc Phelip, et al.
JAMA Oncology|April 4, 2024
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical TrialDavid Tougeron, Laetitia Dahan, Ludovic Evesque, et al.
Clinics and Research in Hepatology and Gastroenterology|February 21, 2022
MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancerEmeric Boisteau, Alexandra Lespagnol, Marie De Tayrac, et al.
Nature|April 22, 2026
Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancerGael Roth, Pascal Artru, Olivier Bouche, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Journal of the National Cancer Institute|February 4, 2016
Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO StudyDavid Tougeron, Guillaume Mouillet, Isabelle Trouilloud, et al.
International Journal of Cancer|January 24, 2020
Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter studyDavid Tougeron, Benjamin Sueur, Aziz Zaanan, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2024
Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world studyJeannie M'Baloula, David Tougeron, Alice Boilève, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 7, 2023
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO studyElisabeth S Bergen, Lorenzo Pilla, Edouard Auclin, et al.
Cancers|July 24, 2021
Management of Patients with Pancreatic Ductal Adenocarcinoma in the Real-Life Setting: Lessons from the French National Hospital DatabaseChristelle de la Fouchardière, Mustapha Adham, Anne-Marie Marion-Audibert, et al.
Oncotarget|December 20, 2017
Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO studyJuliette Palle, David Tougeron, Astrid Pozet, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 5, 2025
Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)Thierry Lecomte, Bruno Giraudeau, Jean-Marc Phelip, et al.
JAMA Oncology|April 4, 2024
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical TrialDavid Tougeron, Laetitia Dahan, Ludovic Evesque, et al.
Clinics and Research in Hepatology and Gastroenterology|February 21, 2022
MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancerEmeric Boisteau, Alexandra Lespagnol, Marie De Tayrac, et al.
Nature|April 22, 2026
Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancerGael Roth, Pascal Artru, Olivier Bouche, et al.
Pageof 9